More recent strategies focus on targeting particular cell types and cytokines using monoclonal antibodies, such as B cell targeting antibodies for MS[13] or anti‐tumor necrosis factor (TNF) antibodies for rheumatoid arthritis.[14] However, even these highly targeted monoclonal therapies do not differentiate between disease‐causing and healthy immune cells, potentially reducing the immune system's capability to fight infectious disease. This evidence concerns the gene TNF and myeloid sarcoma.